Skip to content

Study · Randomized controlled trial · 2009

3 results

Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.

Bouxsein ML, Chen P, Glass EV, Kallmes DF, Delmas PD, Mitlak BH

The Journal of bone and joint surgery. American volume1 Jun 2009Cited by 19 (Europe PMC)

PMID19487509 (opens in a new tab)DOI10.2106/jbjs.h.01030 (opens in a new tab)PepBankPUB-19487509
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide reduced new vertebral fracture risk versus placebo.

    In plain wordsIn postmenopausal women with osteoporosis, teriparatide reduced new spine fracture risk versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseAny new vertebral fracture
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Risk reduction
    72%
    any new vertebral fracture versus placebo

    Source sentences

    Summary
    Teriparatide reduced the risk of any new, new adjacent, and new nonadjacent vertebral fractures by 72%, 75%, and 70%, respectively, compared with the rates in the placebo group.
    1 context sentence
    Summary · context
    Data from the Fracture Prevention Trial and the Multiple Outcomes of Raloxifene Evaluation trial were analyzed to determine the incidences of new adjacent and new nonadjacent vertebral fractures in the placebo groups and the effect of treatment with raloxifene and teriparatide on the incidence of ne…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide reduced new adjacent vertebral fracture risk versus placebo.

    In plain wordsIn postmenopausal women with osteoporosis, teriparatide reduced new fractures beside existing spine fractures versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseNew adjacent vertebral fracture
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Risk reduction
    75%
    new adjacent vertebral fracture versus placebo

    Source sentences

    Summary
    Teriparatide reduced the risk of any new, new adjacent, and new nonadjacent vertebral fractures by 72%, 75%, and 70%, respectively, compared with the rates in the placebo group.
    1 context sentence
    Summary · context
    Data from the Fracture Prevention Trial and the Multiple Outcomes of Raloxifene Evaluation trial were analyzed to determine the incidences of new adjacent and new nonadjacent vertebral fractures in the placebo groups and the effect of treatment with raloxifene and teriparatide on the incidence of ne…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide reduced new nonadjacent vertebral fracture risk versus placebo.

    In plain wordsIn postmenopausal women with osteoporosis, teriparatide reduced new fractures away from existing spine fractures versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseNew nonadjacent vertebral fracture
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Risk reduction
    70%
    new nonadjacent vertebral fracture versus placebo

    Source sentences

    Summary
    Teriparatide reduced the risk of any new, new adjacent, and new nonadjacent vertebral fractures by 72%, 75%, and 70%, respectively, compared with the rates in the placebo group.
    1 context sentence
    Summary · context
    Data from the Fracture Prevention Trial and the Multiple Outcomes of Raloxifene Evaluation trial were analyzed to determine the incidences of new adjacent and new nonadjacent vertebral fractures in the placebo groups and the effect of treatment with raloxifene and teriparatide on the incidence of ne…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.